- News Releases
ROCHESTER, Minn. ― Mayo Clinic Cancer Center announced on Tuesday, Aug. 31, that it is following recommendations from the National Comprehensive Cancer Network that encourage cancer patients to receive a third dose of a messenger RNA COVID-19 vaccine. The Moderna and Pfizer COVID-19 vaccines are messenger RNA vaccines.
If patients were vaccinated with the Johnson & Johnson COVID-19 vaccine, no third dose is recommended at this time. The Johnson & Johnson COVID-19 vaccine is an adenovirus vaccine ― not a messenger RNA vaccine.
"The updated guidelines for cancer patients from NCCN are based on the latest data and approvals from the FDA (Food and Drug Administration) and CDC (Centers for Disease Control and Prevention) regarding administration of a third messenger RNA vaccine dose for cancer patients and immunocompromised people," says Robert McWilliams M.D., a medical oncologist. Dr. McWilliams is chair of Mayo Clinic's Cancer Center Practice Committee.
Here's who should receive a third dose of a messenger RNA COVID-19 vaccine:
Review the updated vaccination guidelines for cancer patients on the National Comprehensive Cancer Network website.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. For information on COVID-19, including Mayo Clinic's Coronavirus Map tracking tool, which has 14-day forecasting on COVID-19 trends, visit the Mayo Clinic COVID-19 Resource Center.
March is Colorectal Cancer Awareness Month, which makes this a good time to learn about the risk factors for colorectal cancer and what you can do ...
Mayo Clinic has been taking care of patients with rectal cancer for more than 100 years, dating back to the Mayo brothers. Even at that ...
ROCHESTER, Minn. — March is Myeloma Awareness Month, and Sikander Ailawadhi, M.D., hematologist/oncologist at Mayo Clinic Comprehensive Cancer Center, shares details about new advancements in ...